Results from an ongoing safety trial of tofacitinib demonstrated an increased risk of blood clots and death associated with a 10-mg twice daily dose of tofacitinib in patients with rheumatoid arthritis.
Top news of the day from across the health care landscape.
Investigators find that radiation equivalent to 3 CT scans prompts the growth of the p53 mutation in mice.
Top news of the week from Specialty Pharmacy Times.
If approved, tazemetostat, a first-in-class EZH2 inhibitor, would be indicated for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
More colorectal cancer cases are being diagnosed in adults under the age of 50, with younger adults presenting with more advanced disease than those older than 50 years.
Long-term use of ivacaftor and other drugs that correct detects in the cystic fibrosis gene could potentially prevent chronic infections from developing.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.